The National Institute for Health and Care Excellence (NICE) are looking for people with multiple sclerosis (MS) or cancer who have personal experience of using cannabis-derived products for...
A recent Australian study has looked at a new potential treatment being developed for multiple sclerosis (MS), which involves extracting a sample of T-cells from the patient’s own immune system.
The...
The US Food & Drugs Administration (FDA) has issued a statement warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than...
Fampridine, also known as Fampyra, has once again been rejected by the Scottish Medical Consortium (SMC) and will not be made available on the NHS in Scotland to multiple sclerosis (MS) patients with...
Upper limb impairment is common in primary progressive multiple sclerosis (PPMS). A recent study, titled ORATORIO, examined the effects of ocrelizumab on confirmed progression and confirmed...
The MS Trust has confirmed that specialist multiple sclerosis (MS) nurses in the UK are handling heavier caseloads than recommended or preferred and, according to the charity’s latest report, means...
B-cells are important in helping the immune system fight pathogens. However, in the case of multiple sclerosis (MS) they can damage nerve tissue. When particular control cells are missing, too many B...
According to a new study, a modified clinical Pilate’s exercise programme had a significant effect on functional capacity and quality of life in multiple sclerosis (MS) patients.
Researchers set out...
According to an announcement by the MS Trust, on 31 October, NICE has delayed its decision on approving ocrelizumab (Ocrevus) for patients with primary progressive multiple sclerosis (PPMS).
The...
Lymphatic vessels that clean the brain of harmful material also play a crucial role in the development and progression of multiple sclerosis (MS), new research from the University of Virginia...
